Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Oct 3:rs.3.rs-3258813.
doi: 10.21203/rs.3.rs-3258813/v1.

Lithium Response in Bipolar Disorder is Associated with Focal Adhesion and PI3K-Akt Networks: A Multi-omics Replication Study

John Kelsoe  1 Anna Ou  1 Sara RosenthalMazda AdliKazufumi Akiyama  2 Nirmala Akula  3 Martin Alda  4 Azmeraw T Amare  5 Raffaella Ardau  6 Bárbara Arias  7 Jean-Michel Aubry  8 Lena BacklundClaudio BanzatoMichael Bauer  9 Bernhard Baune  10 Frank BellivierAntonio BenabarreSusanne BengesserBhattacharjee AbeshJoanna Biernacka  11 Elise BuiPablo Cervantes  12 Guo-Bo ChenHsi-Chung Chen  13 Caterina ChillottiSven Cichon  11 Scott Clark  14 Francesc ColomDavid CousinsCristiana Cruceanu  15 Piotr Czerski  16 Clarissa DantasAlexandre Dayer  17 Franziska Degenhardt  18 J Raymond DePaulo  19 Bruno EtainPeter Falkai  20 Frederike FellendorfEwa Ferensztajn-RochowiakAndreas J Forstner  21 Louise Frisen  22 Mark Frye  11 Janice Fullerton  23 Sebastien GardJulie GarnhamFernando GoesMaria Grigoroiu-Serbanescu  24 Paul GrofOliver GruberRyota Hashimoto  25 Joanna HauserUrs Heilbronner  26 Stefan HermsPer Hoffmann  27 Andrea HofmannLiping Hou  28 Stéphane Jamain  29 Esther JiménezJean-Pierre KahnLayla Kassem  22 Tadafumi Kato  30 Sarah Kittel-SchneiderBarbara KönigPo-Hsiu Kuo  31 Ichiro Kusumi  32 Nina DalknerGonzalo LajeMikael Landén  33 Catharina Lavebratt  34 Marion LeboyerSusan LeckbandCarlos López JaramilloGlenda MacQueenMario Maj  35 Mirko Manchia  4 Cynthia Marie-Claire  36 Lina Martinsson  34 Manuel Mattheisen  19 Michael McCarthySusan McElroy  37 Francis McMahon  38 Philip Mitchell  39 Marina Mitjans  40 Francis Mondimore  23 Palmiero Monteleone  41 Caroline Nievergelt  42 Markus Nöthen  22 Tomas Novak  43 Urban Osby  34 Norio Ozaki  44 Sergi Papiol  20 Roy Perlis  45 Andrea Pfennig  46 James PotashDaniela Reich-ErkelenzAndreas Reif  47 Eva ReininghausMarcella Rietschel  48 Guy Rouleau  49 Janusz K Rybakowski  16 Martin Schalling  34 Peter Schofield  23 Klaus Oliver Schubert  14 Thomas Schulze  50 Barbara SchweizerFlorian SeemüllerGiovanni Severino  51 Tatyana ShekhtmanPaul ShillingKazutaka ShimodaChristian SimhandlClaire SlaneyAlessio Squassina  52 Thomas Stamm  53 Pavla StopkovaSarah TigheAlfonso Tortorella  54 Gustavo Turecki  55 Eduard Vieta  56 Julia VolkertStephanie Witt  57 Naomi Wray  58 Adam WrightTrevor YoungPeter Zandi  19 Maria Del Zompo  51
Affiliations

Lithium Response in Bipolar Disorder is Associated with Focal Adhesion and PI3K-Akt Networks: A Multi-omics Replication Study

John Kelsoe et al. Res Sq. .

Update in

  • Lithium response in bipolar disorder is associated with focal adhesion and PI3K-Akt networks: a multi-omics replication study.
    Ou AH, Rosenthal SB, Adli M, Akiyama K, Akula N, Alda M, Amare AT, Ardau R, Arias B, Aubry JM, Backlund L, Bauer M, Baune BT, Bellivier F, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Cervantes P, Chen GB, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dantas CR, Dayer A, Del Zompo M, Degenhardt F, DePaulo JR, Étain B, Falkai P, Fellendorf FT, Ferensztajn-Rochowiak E, Forstner AJ, Frisén L, Frye MA, Fullerton JM, Gard S, Garnham JS, Goes FS, Grigoroiu-Serbanescu M, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Herms S, Hoffmann P, Hofmann A, Hou L, Jamain S, Jiménez E, Kahn JP, Kassem L, Kato T, Kittel-Schneider S, König B, Kuo PH, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Jaramillo CAL, MacQueen G, Maj M, Manchia M, Marie-Claire C, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, McMahon FJ, Mitchell PB, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Novák T, Ösby U, Ozaki N, Papiol S, Perlis RH, Pisanu C, Potash JB, Pfennig A, Reich-Erkelenz D, Reif A, Reininghaus EZ, Rietschel M, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert KO, Schulze TG, Sch… See abstract for full author list ➔ Ou AH, et al. Transl Psychiatry. 2024 Feb 23;14(1):109. doi: 10.1038/s41398-024-02811-4. Transl Psychiatry. 2024. PMID: 38395906 Free PMC article.

Abstract

Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study of the Pharmacogenomics of Bipolar Disorder (PGBD) sample combining transcriptomic and genomic data, we found that focal adhesion, the extracellular matrix (ECM), and PI3K-Akt signaling networks were associated with response to lithium. In this study, we replicated the results of our previous study using network propagation methods in a genome-wide association study of an independent sample of 2,039 patients from the International Consortium on Lithium Genetics (ConLiGen) study. We identified functional enrichment in focal adhesion and PI3K-Akt pathways, but we did not find an association with the ECM pathway. Our results suggest that deficits in the neuronal growth cone and PI3K-Akt signaling, but not in ECM proteins, may influence response to lithium in BD.

PubMed Disclaimer

Conflict of interest statement

MAd has received a grant from Servier, speaker’s fees from Servier, Lundbeck, Aristo, Parexel, Gilead, ViiV, Deutsche Bank, MSD, and MyTomorrows, plus a non-financial support from Lundbeck. KA has received speaker’s fees from Taisho Toyama Pharmaceutical. MAl is funded by a grant of the Canadian Institutes of Health Research. MB has received speaker’s fees from AstraZeneca, Pfizer, Lilly, Lundbeck, GlaxoSmithKline, Servier, and Ferrer Internacional. BÉ received non-financial support from Labex Biopsy and Fondation Fondamental. RH received grants and speaker honoraria from Dainippon Sumitomo Pharma and Novartis plus speaker honoraria from Eli Lilly Japan, GlaxoSmithKline, Hisamitsu Pharmaceutical, Janssen Pharmaceutical, Nippon Zoki Pharmaceutical, Otsuka Pharmaceutical, Astellas Pharma, Pfizer, and the Yoshitomiyakuhin Corporation. TK received a grant from Takeda Pharmaceutical and fees from Kyowa Hakko Kirin, Eli Lilly Japan, Otsuka Pharmaceutical, GlaxoSmithKline, Taisho Toyama Pharmaceutical, Dainippon Sumitomo Pharma, Meiji Seika Pharma, PfizerJapan, Mochida Pharmaceutical, Shionogi & Co, Janssen Pharmaceutical, Yoshitomiyakuhin Corporation, Agilent Technologies, Astellas Pharma, and Wako Pure Chemical Industries. IK received grants and fees from Dainippon Sumitomo Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Kyowa Hakko Kirin, Meiji Seika Pharma, MSD, Novartis, Otsuka, Ono Pharmaceutical, Pfizer, Tanabe Mitsubishi Pharma, Takeda Pharmaceutical, Shionogi, and Yoshitomi Pharmaceutical; he received grants from AbbVie GK, Asahi Kasei Pharma, Boehringer Ingelheim, Chugai Pharmaceutical, and Daiichi Sankyo and fees from Astellas Pharma and Janssen Pharmaceutical. MJM served as unpaid consultant for Pathway Genomic (San Diego, USA). SLM received a grant and fees from Naurex and Shire, further grants from Alkermes, Cephalon, Forest, Marriott Foundation, Orexigen Therapeutics, and Takeda Pharmaceutical, he further has served on the advisory boards for Bracket, Hoffmann-La Roche, MedAvante, Sunovion and received fees from Novo Nordisk. RHP received personal fees from RID Ventures, Genomind LLC, Healthrageous, P zer, Perfect Health, Proteus, and Psybrain. PRS received a grant from NHMRC. TGS received a grant and fees from Roche Pharmaceuticals. TSt received personal fees from Servier, Lundbeck, and Bristol-Myers Squibb. MM has received grants from Lundbeck and Angelini. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Janssen, Lundbeck, Medincell, Merck, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, and Viatris, outside the submitted work. SRC has participated in advisory and educational boards and received speaker’s fees from Janssen-Cilag, Lundbeck, Otsuka, and Servier; research funding from Janssen-Cilag, Lundbeck, Otsuka, and Gilead; and data sharing from Viatris Australia. ML has received lecture honoraria from Lundbeck pharmaceuticals. All above listed interests are outside of the submitted work. All other authors declare no competing interests.

Figures

Figure 1
Figure 1. Overlap Between KEGG Focal adhesion and Top 500 Genes
KEGG hsa04510 pathway for focal adhesion adapted to illustrate gene overlap. Genes in yellow overlap with the 500 gene NAGA network.
Figure 2
Figure 2. Overlap Between KEGG ECM-receptor interaction and Top 500 Genes
KEGG hsa04512 pathway for ECM-receptor interaction adapted to illustrate gene overlap. Genes in yellow overlap with the 500 gene NAGA network.
Figure 3
Figure 3. Overlap Between KEGG PI3k-Akt and Top 500 Genes
KEGG hsa04151 pathway for PI3k-Akt signaling adapted to illustrate gene overlap. Genes in yellow overlap with the 500 gene NAGA network.

References

    1. Dome P., Rihmer Z. & Gonda X. Suicide Risk in Bipolar Disorder: A Brief Review. Medicina 55, (2019). - PMC - PubMed
    1. Cipriani A., Hawton K., Stockton S. & Geddes J. R. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346, f3646 (2013). - PubMed
    1. Plans L. et al. Association between completed suicide and bipolar disorder: A systematic review of the literature. J. Affect. Disord. 242, 111–122 (2019). - PubMed
    1. Sajatovic M. Bipolar disorder: disease burden. Am. J. Manag. Care 11, S80–4 (2005). - PubMed
    1. Rybakowski J. K. Lithium. Eur. Neuropsychopharmacol. 57, 86–87 (2022). - PubMed

Publication types

LinkOut - more resources